Outcomes Mandate National Integration With Cannabis as Medicine

Trial ID: NCT03944447

Interventional - Phase 2 - Unknown status

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

Conditions

• Chronic Pain
• Chronic Pain Syndrome
• Chronic Pain Due to Injury
• Chronic Pain Due to Trauma
• Fibromyalgia
• Seizures
• Hepatitis C
• Cancer
• Crohn Disease
• HIV/AIDS
• Multiple Sclerosis
• Traumatic Brain Injury
• Sickle Cell Disease
• Post Traumatic Stress Disorder
• Tourette Syndrome
• Ulcerative Colitis
• Glaucoma
• Epilepsy
• Inflammatory Bowel Diseases
• Parkinson Disease
• Amyotrophic Lateral Sclerosis
• Chronic Traumatic Encephalopathy
• Anxiety
• Depression
• Insomnia
• Autism
• Opioid-use Disorder
• Bipolar Disorder
• Covid19
• SARS-CoV Infection
• COVID-19
• Corona Virus Infection
• Coronavirus

Interventions

• Cannabis, Medical
• RYAH-Medtech Inhaler

Eligibility

Inclusion criteria

• Clinical diagnosis of a Qualifying Condition for Medical Marijuana
• Must be 18 years or older unless they have consent from their parent or legal guardian as defined under state law parameters
• Must be willing to complete online surveys at baseline and the follow up points in this study

Exclusion criteria

• Pregnancy
• Breastfeeding
• Inability to provide informed consent
• Inability to complete study visits or questionnaires
• Active suicidality or psychosis, that could be exacerbated by the administration of cannabis

Sponsor

OMNI Medical Services, LLC, OMNI Medical Services Inc

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows